


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

**INNOVATIVE MEDICINE “TQ-B3525 TABLETS (PI3K δ/α DUAL INHIBITOR)”
FOR TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR
LYMPHOMA SUBMITTED A MARKETING APPLICATION**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that a new drug marketing application for the Category 1 innovative anti-tumor medicine TQ-B3525 Tablets (PI3K δ/α dual inhibitor) has been submitted to and accepted by the Center for Drug Evaluation of the National Medical Products Administration of the People’s Republic of China for the treatment of relapsed or refractory follicular lymphoma with at least previous second-line systemic therapy.

In 2020, the number of new cases of non-Hodgkin’s lymphoma (NHL) in China exceeded 92,800 per year. Follicular lymphoma (FL) is the second most common form of NHL, accounting for approximately 8.1% to 23.5% of NHL in China, and approximately 80% of patients have advanced disease (stage III/IV) at the time of diagnosis. Although follicular lymphoma is classified as an indolent lymphoma, the vast majority of patients will have multiple recurrences of progressive and aggressive disease, which may result in death within one to two years. FL is currently an incurable disease with limited treatment options and an unmet clinical need for relapsed/refractory follicular lymphoma in China.

TQ-B3525 Tablets are highly selective dual inhibitors of phosphoinositide 3-kinase δ/α (PI3K δ/α), which inhibit the proliferation of malignant tumor cells by inhibiting the expression of PI3K protein and reducing AKT protein phosphorylation levels, thereby inducing apoptosis. TQ-B3525 Tablets selectively inhibit both PI3K δ and PI3K α subunits, overcoming the resistance problems caused by upregulation of PI3K α activity due to PI3K δ inhibition alone. Early clinical data confirmed the efficacy of TQ-B3525 Tablets in advanced malignancies such as relapsed/refractory follicular lymphoma. In July 2021, TQ-B3525 Tablets was included as a breakthrough therapy for relapsed/refractory follicular lymphoma where at least previous second-line therapy had failed.

TQ-B3525 Tablets are another Category 1 innovative drug recently submitted by the Group for marketing application after TQB3139 Capsules, TQ-B3101 Capsules and TQB2450 Injection. The Group has been making breakthroughs in the research and development of innovative drugs and its new drug pipeline has gradually entered the harvesting phase.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 23 May 2023

As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.